Research programme: cancer therapeutics - AbbVie/Johns Hopkins University
Latest Information Update: 09 Dec 2016
At a glance
- Originator AbbVie; Johns Hopkins University School of Medicine
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Dec 2016 AbbVie and the Johns Hopkins University School of Medicine sign a five-year collaboration agreement for the discovery and development of therapies for Cancer
- 05 Dec 2016 Preclinical trials in Cancer in USA (unspecified route)